Overview

Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to validate [11C]ORM-13070 as an alpha2C-adrenoceptor imaging agent for human positron emission tomography (PET) studies of brain alpha2C-adrenoceptor occupancy.
Phase:
Phase 1
Details
Lead Sponsor:
University of Turku
Collaborator:
Orion Corporation, Orion Pharma
Treatments:
Atipamezole
Atomoxetine Hydrochloride
Insulin
Insulin, Globin Zinc
Ketamine
Norepinephrine